SHIRE PLC: Director/PDMR Shareholding

 Director/PDMR Share Dealings  April 1, 2014 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces that it was notified on March 31, 2014 that on that day Ordinary Shares ("Shares") and American Depository Shares ("ADSs") of the Company, as set out below, had been awarded under the Shire Executive Annual Incentive Plan ("EAIP") to Persons Discharging Managerial Responsibility ("PDMRs"). The Shares and ADSs were acquired on March 31, 2014 at prices of £29.8997 per Share and $147.64 per ADS.                                               Type of       Number of                                                Security                                                                               Securities                                                                           Flemming Ornskov                            ADSs           2,703                                                                             Tatjana May                                Shares          4,176         The awards will normally be released to participants after a period of three years. One ADS is equal to three Shares.  In addition, the Company was notified on March 31, 2014 of the release of the following Shares awarded in 2011 under the EAIP.                                             Number of    Number of Shares                                           Shares      sold to satisfy                                            released    tax liabilities                                                                       Tatjana May                                4,517                 2,139  On March 31, 2014 sufficient Shares were sold to satisfy tax liabilities as set out above. The Shares were sold at a price of £29.8076 per Share.  The above transactions in Shares and ADSs took place on the London Stock Exchange and NASDAQ respectively.  This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.  Tony Guthrie Deputy Company Secretary  For further information please contact:  Investor Relations                                                                                                                                           Laurie Stelzer                          lstelzer@shire.com   +1 781 482 0733                                                                                 Eric Rojas                              erojas@shire.com     +1 781 482 0999                                                                                 Sarah Elton-Farr                        seltonfarr@shire.com +44 1256 894157     Notes to editors  Shire enables people with life-altering conditions to lead better lives.  Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.  We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.  Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX  Press Release                                                                                      www.shire.com                                       END